Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 01:03PM ET
26.76
Dollar change
-0.49
Percentage change
-1.80
%
IndexRUT P/E- EPS (ttm)-2.94 Insider Own8.06% Shs Outstand90.28M Perf Week-3.43%
Market Cap2.42B Forward P/E- EPS next Y-1.84 Insider Trans-4.72% Shs Float83.21M Perf Month-7.82%
Income-245.59M PEG- EPS next Q-0.68 Inst Own96.04% Short Float12.31% Perf Quarter-16.22%
Sales0.00M P/S- EPS this Y7.00% Inst Trans5.54% Short Ratio13.81 Perf Half Y25.69%
Book/sh5.46 P/B4.90 EPS next Y32.23% ROA-43.93% Short Interest10.24M Perf Year69.47%
Cash/sh4.12 P/C6.49 EPS next 5Y41.70% ROE-50.01% 52W Range14.89 - 32.53 Perf YTD-10.71%
Dividend Est.- P/FCF- EPS past 5Y-9.09% ROI-47.70% 52W High-17.72% Beta1.07
Dividend TTM- Quick Ratio7.80 Sales past 5Y0.00% Gross Margin- 52W Low79.72% ATR (14)1.22
Dividend Ex-Date- Current Ratio7.80 EPS Y/Y TTM10.53% Oper. Margin0.00% RSI (14)43.63 Volatility3.83% 4.78%
Employees268 Debt/Eq0.05 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price50.27
Option/ShortYes / Yes LT Debt/Eq0.05 EPS Q/Q30.17% Payout- Rel Volume0.25 Prev Close27.25
Sales Surprise- EPS Surprise17.79% Sales Q/Q- EarningsFeb 26 AMC Avg Volume741.62K Price26.76
SMA20-3.23% SMA50-5.59% SMA20017.83% Trades Volume104,117 Change-1.80%
Date Action Analyst Rating Change Price Target Change
Oct-24-23Initiated Cantor Fitzgerald Overweight $65
Feb-01-23Initiated Morgan Stanley Overweight $45
Nov-08-22Initiated Canaccord Genuity Buy $53
Nov-01-22Initiated BTIG Research Buy $35
Jul-08-22Initiated Raymond James Outperform $22
Oct-20-21Resumed Cowen Outperform
Mar-02-21Initiated Stifel Buy $64
Feb-18-21Initiated Needham Buy $75
Dec-16-20Initiated UBS Buy $75
Dec-08-20Downgrade Oppenheimer Outperform → Perform
Mar-27-24 11:30AM
Mar-26-24 04:01PM
Feb-27-24 12:20PM
Feb-26-24 04:01PM
Feb-13-24 07:00AM
03:39AM Loading…
Jan-22-24 03:39AM
Jan-04-24 11:55AM
Jan-02-24 04:01PM
Dec-12-23 07:00AM
Nov-23-23 12:16PM
Nov-15-23 11:17AM
Nov-09-23 09:55AM
Nov-06-23 04:15PM
04:04PM
Nov-05-23 07:30AM
06:26PM Loading…
Nov-02-23 06:26PM
Oct-27-23 02:49PM
Oct-20-23 03:18AM
Oct-19-23 07:00AM
Oct-02-23 07:00AM
Sep-26-23 04:01PM
Sep-23-23 09:45AM
Sep-18-23 07:30AM
Sep-15-23 11:00AM
Sep-14-23 10:12AM
Sep-13-23 04:34PM
01:50PM
01:36PM
12:30PM
12:23PM
12:15PM Loading…
12:15PM
11:56AM
10:54AM
07:24AM
12:01AM
Sep-12-23 04:02PM
04:01PM
Sep-06-23 04:05PM
Aug-10-23 07:14AM
07:00AM
Jul-29-23 11:39AM
Jul-28-23 03:57PM
Jun-12-23 04:34PM
Jun-09-23 09:24AM
Jun-08-23 07:00AM
May-31-23 07:00AM
May-23-23 07:00AM
May-19-23 06:00AM
May-18-23 06:12AM
May-17-23 04:26PM
May-09-23 07:00AM
May-04-23 04:21PM
04:01PM
May-03-23 04:01PM
Apr-11-23 04:01PM
Apr-04-23 04:01PM
Mar-01-23 04:01PM
Feb-27-23 04:01PM
Feb-09-23 04:01PM
Feb-07-23 07:00AM
Feb-05-23 09:07AM
Jan-28-23 01:30PM
Jan-23-23 10:15AM
09:55AM
Jan-09-23 04:01PM
Jan-06-23 09:55AM
Jan-03-23 04:01PM
Dec-22-22 06:00AM
Dec-12-22 10:00AM
Dec-11-22 07:21PM
Dec-01-22 04:01PM
Nov-21-22 08:00AM
Nov-16-22 07:59AM
Nov-03-22 04:01PM
09:00AM
Oct-27-22 09:55AM
Oct-14-22 06:35PM
Oct-12-22 06:00AM
Oct-11-22 09:55AM
Oct-10-22 08:00AM
Oct-03-22 11:21PM
04:42PM
Sep-30-22 06:00AM
Sep-27-22 08:00AM
Sep-20-22 05:07PM
11:14AM
10:06AM
06:00AM
Sep-16-22 08:00AM
Sep-06-22 08:00AM
Aug-15-22 09:13AM
Aug-11-22 02:11PM
Aug-08-22 04:01PM
Jul-27-22 07:00AM
Jul-20-22 06:33AM
Jul-08-22 01:58PM
07:00AM
Jun-01-22 11:02AM
May-19-22 11:14AM
06:00AM
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in Cranbury, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Makker GothamDirectorMar 21 '24Sale28.43274,0007,790,943365,912Mar 25 08:58 PM
Militello JohnSee RemarksMar 21 '24Sale28.102,49069,97955,239Mar 25 08:54 PM
Militello JohnSee RemarksFeb 29 '24Option Exercise12.5510,000125,50031,517Mar 04 06:54 PM
Militello JohnSee RemarksFeb 29 '24Sale29.8410,000298,45021,517Mar 04 06:54 PM
Wilson MartinGeneral CounselFeb 29 '24Sale29.334,100120,25718,680Mar 04 06:48 PM
Shah GauravCEOFeb 16 '24Sale29.8420,272604,876554,762Feb 21 08:54 PM
Patel KinnariSee RemarksFeb 16 '24Sale29.847,132212,805238,346Feb 21 08:54 PM
Wilson MartinGeneral CounselFeb 16 '24Sale29.843,576106,7016,136Feb 21 08:54 PM
Militello JohnSee RemarksFeb 16 '24Sale29.843,23896,61513,195Feb 21 08:54 PM
Militello JohnSee RemarksFeb 14 '24Option Exercise0.006,274016,433Feb 16 04:05 PM
Patel KinnariSee RemarksFeb 14 '24Option Exercise0.0026,1890245,478Feb 16 04:05 PM
Militello JohnSee RemarksJan 22 '24Sale27.2063817,35610,159Jan 23 04:22 PM
Militello JohnSee RemarksJan 18 '24Option Exercise0.001,586010,797Jan 22 04:05 PM
Makker GothamDirectorNov 15 '23Sale22.5320,000450,6461,296,497Nov 16 07:24 PM
Patel KinnariSee RemarksNov 14 '23Option Exercise0.003,9890220,437Nov 16 07:17 PM
Militello JohnSee RemarksNov 14 '23Option Exercise0.0072509,485Nov 16 06:58 PM
Militello JohnSee RemarksOct 20 '23Sale17.065649,6238,760Oct 25 09:38 AM
Patel KinnariSee RemarksOct 05 '23Option Exercise0.003,3330101,594Oct 10 04:11 PM
Makker GothamDirectorSep 29 '23Sale21.144,67798,8641,316,497Oct 02 09:02 PM
Makker GothamDirectorSep 28 '23Sale21.0310,312216,8801,321,174Oct 02 09:02 PM
Shah GauravCEOAug 17 '23Sale15.474,76773,750524,854Aug 21 04:05 PM
Patel KinnariSee RemarksAug 17 '23Sale15.471,53423,733216,448Aug 21 04:05 PM
Militello JohnSee RemarksAug 17 '23Sale15.472844,3945,570Aug 21 04:05 PM
Patel KinnariSee RemarksAug 14 '23Option Exercise0.003,9890217,982Aug 15 04:16 PM
Militello JohnSee RemarksAug 14 '23Option Exercise0.0072507,854Aug 15 04:17 PM
Shah GauravCEOAug 14 '23Option Exercise0.007,9790529,621Aug 15 04:06 PM
Militello JohnSee RemarksJul 20 '23Sale19.0357310,9067,129Jul 24 04:05 PM
Militello JohnSee RemarksJul 18 '23Option Exercise0.001,58607,702Jul 20 04:05 PM
Shah GauravCEOMay 17 '23Sale21.384,12288,108521,642May 19 04:05 PM
Patel KinnariSee RemarksMay 17 '23Sale21.381,33028,429213,993May 19 04:05 PM
Militello JohnSee RemarksMay 17 '23Sale21.382455,2376,116May 19 04:05 PM
Militello JohnSee RemarksMay 14 '23Option Exercise0.0072506,361May 16 08:01 PM
Shah GauravCEOMay 14 '23Option Exercise0.007,9790525,764May 16 08:04 PM
Patel KinnariSee RemarksMay 14 '23Option Exercise0.003,9890215,323May 16 07:57 PM
Militello JohnSee RemarksApr 21 '23Sale18.652,34243,6785,636Apr 25 06:33 PM
Militello JohnSee RemarksApr 18 '23Option Exercise0.006,36407,978Apr 20 06:34 PM